{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Evaluate+the+Safety", "query": { "condition": "Evaluate the Safety" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 11760, "total_pages": 1176, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Evaluate+the+Safety&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T19:01:38.381Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT03358472", "title": "Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Epacadostat", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "5-Fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 89, "start_date": "2017-12-01", "completion_date": "2025-10-30", "has_results": true, "last_update_posted_date": "2025-12-03", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 14, "location_summary": "Anaheim, California • Sacramento, California • Santa Rosa, California + 11 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT03358472" }, { "nct_id": "NCT02603081", "title": "Study to Evaluate SPI-1005 in Adults With Meniere's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Meniere's Disease" ], "interventions": [ { "name": "SPI-1005", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sound Pharmaceuticals, Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "19 Years to 70 Years" }, "enrollment_count": 40, "start_date": "2015-12", "completion_date": "2017-08", "has_results": true, "last_update_posted_date": "2026-06-29", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 5, "location_summary": "Los Angeles, California • New York, New York • Charleston, South Carolina + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "Charleston", "state": "South Carolina" }, { "city": "Seattle", "state": "Washington" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02603081" }, { "nct_id": "NCT01224067", "title": "Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Social Anxiety Disorder" ], "interventions": [ { "name": "Quetiapine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cambridge Health Alliance", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 40, "start_date": "2006-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2017-04-18", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 1, "location_summary": "Cambridge, Massachusetts", "locations": [ { "city": "Cambridge", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01224067" }, { "nct_id": "NCT00150800", "title": "This Trial, Evaluating the Long-term Safety and Tolerability of Brivaracetam Will Provide Subjects Suffering From Epilepsy, Who May Have Benefited From Brivaracetam as Adjunctive Treatment, the Opportunity to Receive Open Label Brivaracetam Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Epilepsy" ], "interventions": [ { "name": "Brivaracetam", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "UCB PHARMA Inc. (US)", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "16 Years", "maximum_age": null, "sex": "ALL", "summary": "16 Years and older" }, "enrollment_count": 668, "start_date": "2006-01", "completion_date": "2017-09", "has_results": true, "last_update_posted_date": "2021-08-17", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 46, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 38 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00150800" }, { "nct_id": "NCT00226395", "title": "Efficacy and Safety of Oxymorphone Immediate Release in Post-surgical Acute Pain", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Acute Pain" ], "interventions": [ { "name": "Oxymorphone immediate release", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Endo USA Inc., a Keenova Therapeutics Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 320, "start_date": "2004-09", "completion_date": "2005-08", "has_results": false, "last_update_posted_date": "2024-01-02", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 21, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Phoenix, Arizona + 10 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00226395" }, { "nct_id": "NCT07342881", "title": "Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Chronic Hepatitis B Infection" ], "interventions": [ { "name": "Pevifoscorvir Sodium (ALG-000184)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Aligos Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 30, "start_date": "2026-02-20", "completion_date": "2026-07-01", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 2, "location_summary": "Orlando, Florida • Tampa, Florida", "locations": [ { "city": "Orlando", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07342881" }, { "nct_id": "NCT06195930", "title": "A Study to Learn How Safe Starting Vericiguat at a Dose of 5 Milligrams is in Participants With Chronic Heart Failure With Reduced Ejection Fraction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Heart Failure With Reduced Ejection Fraction" ], "interventions": [ { "name": "Vericiguat (BAY1021189) 5 mg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 106, "start_date": "2024-04-18", "completion_date": "2024-07-29", "has_results": true, "last_update_posted_date": "2025-09-25", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 5, "location_summary": "Alexander City, Alabama • Richmond, Indiana • Baltimore, Maryland + 2 more", "locations": [ { "city": "Alexander City", "state": "Alabama" }, { "city": "Richmond", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT06195930" }, { "nct_id": "NCT02261467", "title": "A Safety and Efficacy Study of OnabotulinumtoxinA in Forehead and Glabellar Facial Rhytides", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Forehead Rhytides", "Glabellar Rhytides" ], "interventions": [ { "name": "OnabotulinumtoxinA", "type": "BIOLOGICAL" }, { "name": "Normal Saline", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 421, "start_date": "2014-10-21", "completion_date": "2016-04-26", "has_results": true, "last_update_posted_date": "2019-01-08", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Glendale, Arizona • Santa Monica, California + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Glendale", "state": "Arizona" }, { "city": "Santa Monica", "state": "California" }, { "city": "Greenwood Village", "state": "Colorado" }, { "city": "Boca Raton", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02261467" }, { "nct_id": "NCT01187836", "title": "Study to Evaluate the Effects of TRV120027 in Patients With Heart Failure", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Heart Failure" ], "interventions": [ { "name": "TRV120027", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Trevena Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "18 Years to 79 Years" }, "enrollment_count": 33, "start_date": "2010-12", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2017-07-11", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 4, "location_summary": "Miami, Florida • Baltimore, Maryland • Boston, Massachusetts + 1 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01187836" }, { "nct_id": "NCT07424144", "title": "An Extension Study to Investigate the Long-term Safety and Tolerability of Itepekimab in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps", "overall_status": "ENROLLING_BY_INVITATION", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Rhinosinusitis With Nasal Polyps" ], "interventions": [ { "name": "Itepekimab (SAR440340)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 380, "start_date": "2026-03-12", "completion_date": "2028-12-12", "has_results": false, "last_update_posted_date": "2026-06-22", "last_synced_at": "2026-07-23T19:01:38.381Z", "location_count": 2, "location_summary": "La Mesa, California • Oklahoma City, Oklahoma", "locations": [ { "city": "La Mesa", "state": "California" }, { "city": "Oklahoma City", "state": "Oklahoma" } ], "official_url": "https://clinicaltrials.gov/study/NCT07424144" } ] }